Compounders Say FDA Guidance on Interim GMPs is Subjective, Unclear

Drug Industry Daily
Compounding pharmacies are asking the FDA to overhaul its guidance for interim good manufacturing practices, contending the recommendations for such things as the cleanliness of air filters and presence of particulates are unclear and subjective.

To View This Article:


Subscribe To Drug Industry Daily